Short answer · Medically reviewed summary · Last updated: 2023-07-13
PMM2-CDG (Phosphomannomutase 2-congenital disorder of glycosylation) is a rare genetic disorder that affects the body's ability to produce certain proteins and sugars. It is estimated to have a prevalence of approximately 1 in 20,000 to 1 in 50,000 individuals worldwide. Individuals with PMM2-CDG may experience a wide range of symptoms, including developmental delays, intellectual disability, liver dysfunction, muscle weakness, and impaired blood clotting.
What is the prevalence of PMM2-CDG?
Prevalence of PMM2-CDG: how many people are affected worldwide, differences by sex and region, with sources.
PMM2-CDG (Phosphomannomutase 2-congenital disorder of glycosylation) is a rare genetic disorder that affects the body's ability to produce certain proteins and sugars. It is estimated to have a prevalence of approximately 1 in 20,000 to 1 in 50,000 individuals worldwide.
Individuals with PMM2-CDG may experience a wide range of symptoms, including developmental delays, intellectual disability, liver dysfunction, muscle weakness, and impaired blood clotting. The severity of the condition can vary significantly from person to person.
Due to its rarity, PMM2-CDG often goes undiagnosed or misdiagnosed, making it challenging to determine the exact prevalence. However, advancements in genetic testing and increased awareness have led to improved identification and understanding of this disorder.
While there is currently no cure for PMM2-CDG, management focuses on addressing individual symptoms and providing supportive care. Early intervention and multidisciplinary approaches involving various medical specialists can help improve the quality of life for individuals with PMM2-CDG.
